OGLUFANIDE SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H17N3O5.2Na
Molecular Weight	377.3028
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].N[C@@H](CCC([O-])=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C([O-])=O

InChI

InChIKey=GDLPAGOVHZLZEK-JBUFHSOLSA-L

InChI=1S/C16H19N3O5.2Na/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12;;/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24);;/q;2*+1/p-2/t11-,13-;;/m0../s1

HIDE SMILES / InChI

Molecular Formula	C16H17N3O5
Molecular Weight	331.3233
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://cytomed.ru/timogen/ | https://www.hrsa.gov/sites/default/files/opa/programrequirements/orphandrugexclusion/janmar2015list.pdf | https://adisinsight.springer.com/drugs/800010303 | https://www.hepatitiscentral.com/news/oglufanide_bein/

Oglufanide, an angiogenesis inhibitor, an immunomodulator, that originally was developed and registered in Russia under the brand name timogen. Oglufanide inhibits vascular endothelial growth factor (VEGF), which may inhibit angiogenesis. This agent has also been reported to stimulate the immune response to hepatitis C virus and intracellular bacterial infections. Oglufanide was studied in the USA for the treatment of cancer, and in September 2001, it was granted Orphan Drug designation for the treatment of ovarian cancer. In addition, in Australia this drug was involved in phase II clinical trial for the treatment of hepatitis C. Oglufanide is also participated in phase III trials for patients with Kaposi's sarcoma, however, this study was discontinued.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vascular endothelial growth factor 2 Target ID: Vascular endothelial growth factor Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oglufanide-disodium	Inhibitor 8297

PubMed

Title	Date	PubMed
[Conjugates of 2',3'-didehydro-3'-deoxythymidine with thymogen. Synthesis and anti-HIV activity].	1999 Jul	10563202
Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells.	2006 Feb	16984110
The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice.	2007 Mar	17276896
Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation.	2008	18428206

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:37:53 GMT 2023` Edited by `admin` on `Fri Dec 15 16:37:53 GMT 2023`
Record UNII	Q60AU1LLNU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OGLUFANIDE SODIUM

Common Name

English

L-.ALPHA.-GLUTAMYL-L-TRYPTOPHAN, DISODIUM SALT

Common Name

English

GLUFANIDE DISODIUM

Common Name

English

Oglufanide disodium [WHO-DD]

Common Name

English

Oglufanide sodium [WHO-DD]

Common Name

English

OGLUFANIDE DISODIUM [USAN]

Common Name

English

IM862

Code

English

L-TRYPTOPHAN,L-.ALPHA.-GLUTAMYL-, DISODIUM SALT

Common Name

English

IM-862

Code

English

OGLUFANIDE DISODIUM

Official Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1742